Serum concentrations of valproic acid in people with epilepsy: Clinical implication

• Main Authors: Angel T. Alvarado (Author), Juan Cotuá (Author), Maryori Delgado (Author), Alexis Morales (Author), Ana María Muñoz (Author), César Li Amenero (Author), María R. Bendezú (Author), Jorge A. García (Author), Doris Laos-Anchante (Author), Felipe Surco-Laos (Author), Berta Loja (Author), Mario Bolarte-Arteaga (Author), Mario Pineda-Pérez (Author)
• Format: Book
• Published: GarVal Editorial Ltda., 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

Item Description

https://doi.org/10.56499/jppres22.1500_10.6.1117
0719-4250